Cleo Diagnostics (ASX:COV) Tax Expense: A$0.00 Mil (TTM As of Dec. 2025)


ASX:COV Cleo Diagnostics Ltd ASX:COV
17 GF Score
Price A$0.50
! 1 Warning Sign
View Full Analysis

What is Cleo Diagnostics Tax Expense?

Cleo Diagnostics ASX:COV -1.98% 17 Tax Expense is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:COV with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Cleo Diagnostics's tax expense for the months ended in Dec. 2025 was A$0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.


Cleo Diagnostics  (ASX:COV) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Cleo Diagnostics Tax Expense Related Terms


Cleo Diagnostics Tax Expense Historical Data

* Premium members only.

The historical data trend for Cleo Diagnostics's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cleo Diagnostics Tax Expense Chart

Cleo Diagnostics Annual Data
Trend Jun23 Jun24 Jun25
Tax Expense
0.00 0.00 0.00

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Tax Expense Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
ASX:COV
17GF Score
Cleo Diagnostics Ltd ASX:COV
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cleo Diagnostics Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of A$0.00 Mil mean?
Cleo Diagnostics (ASX:COV) has a Tax Expense of A$0.00 Mil as of Dec. 2025. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Cleo Diagnostics and its competitors.
Is Cleo Diagnostics' Tax Expense too high?
Cleo Diagnostics' current Tax Expense is A$0.00 Mil. Overall, Cleo Diagnostics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' Tax Expense compare to ABT and SYK?
Cleo Diagnostics' Tax Expense of A$0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Medical Devices & Instruments company?
A good Tax Expense depends on the Medical Devices & Instruments industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Cleo Diagnostics and its competitors. Cleo Diagnostics's current Tax Expense is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current Tax Expense of A$0.00 Mil. The current Tax Expense is A$0.00 Mil. Cleo Diagnostics' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current Tax Expense is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cleo Diagnostics Business Description

Address 480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
17GF Score

Get the complete analysis for ASX:COV

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.50
Price